T2 Biosystems is creating a new generation of lab-quality diagnostic tools. Its technology is based on superparamagnetic nanoparticles. NanoDx particles have a superparamagnetic metal core surrounded by a polymer layer decorated by multiple analyte-specific binding agents. This nanoparticle platform can be used with a variety of binding agents such as antibodies, nucleic acids and small molecules.
Tempo is focused on significantly improving the efficacy and safety profile of existing and new drugs employing advances in nanotechnology. The Company utilizes its proprietary Nanocell™ technology to develop multi-compartmental, nanoparticle-based therapeutics in which two drugs with varied release rates are packaged within a single nanoparticle.
The company has leveraged its experience with magnetic nanomaterials and magnetic field energy to make antibodies tumoricidal and more therapeutically selective, without the side effects of conventional therapies.
Developed and manufactures a novel, biomaterial which utilizes hydrogel nanoparticles which aggregate to form a material of varying strength and elasticity which has extensive medical application including wound management and burn care, tissue regeneration and drug delivery devices.
Vascular Magnetics, Inc. is magnetically targeting drug-loaded biodegradable nanoparticles to develop Vascular Magnetic Intervention (VMI), a novel therapy for peripheral artery disease (PAD). PAD is a common chronic condition characterized by obstruction (stenosis) of the arteries in the legs.
The company is developing Drug-Coated Balloons (DCB) that are designed to be a more precise delivery vehicle and be the standard treatment of choice for vascular atherosclerosis as well as non-vascular applications.
WaferGen Biosystems, Inc. is a leader in the development, manufacture and commercialization of next-generation systems for gene expression, genotyping, stem cell research and cell biology for the life science and pharmaceutical industries.
WaveSense develops, manufactures, and markets breakthrough analytical nanotechnologies for use in cellular and molecular assay markets. The company's patented and hierarchy technology is called Xenographic Retention Chromatography (XRC) - branded as EpiSep, which is a lateral flow separations platform that provides rapid, advanced detection and characterization of live cells, proteins, and/or genes. Researchers can then harvest the targets for interrogation purposes within their desired application.